Key Highlights:
- Johnson & Johnson seeks FDA approval to expand Capylta's use to include relapse prevention in schizophrenia.
- Wall Street analysts provide an average price target of $170.05 for JNJ, suggesting potential growth.
- GuruFocus estimates a substantial upside of 20.68% based on the GF Value metric.
Johnson & Johnson (JNJ, Financial) is actively seeking approval from the U.S. FDA to broaden the application of its antipsychotic drug, Capylta. The expansion aims to incorporate relapse prevention for schizophrenia, adding to its current approvals for treating schizophrenia and managing bipolar-related depressive episodes in adults.
Wall Street Analysts' Forecast
According to 24 analysts' one-year price targets, the average target price for Johnson & Johnson (JNJ, Financial) stands at $170.05, with estimates ranging from a high of $185.00 to a low of $150.00. This average target price represents a potential upside of 9.68% from the current stock price of $155.04. For more comprehensive estimate data, please visit the Johnson & Johnson (JNJ) Forecast page.
Analyst Recommendations
The consensus from 25 brokerage firms rates Johnson & Johnson (JNJ, Financial) with an average brokerage recommendation of 2.4, which translates to "Outperform." The rating scale ranges from 1 (Strong Buy) to 5 (Sell), indicating a strong confidence level in the company's future performance among analysts.
GF Value Estimation
Based on GuruFocus estimates, the projected GF Value for Johnson & Johnson (JNJ, Financial) in one year is $187.11. This estimate implies a significant upside of 20.68% from the current price of $155.04. The GF Value is derived from historical trading multiples, past business growth, and future performance projections. For more detailed information, visit the Johnson & Johnson (JNJ) Summary page.
